Effect of exchange transfusion with Fluosol DA 20% on splenic distribution and immunocompetence of rat lymphocytes.
T- and B-splenic lymphocyte frequency, immune response 4 days after immunization with sheep red blood cells (SRBC), and proliferative response to concanavalin A (Con A) were determined 1, 3, and 5 days after exchange transfusion with Fluosol DA 20% (FDA) in adult, male Sprague-Dawley rats vs sham transfused rats. T-cell, T-helper, T-suppressor, and B-lymphocyte were reduced 1 day after transfusion (P less than or equal to 0.001). T- and B-lymphocyte frequencies were still reduced at day 3 (P = 0.0372). By day 5, there were no significant reductions in T-cell, T-helper, T-suppressor, and B-cell frequencies in the FDA-transfused rats. The frequency of cells with cytoplasmic IgG was reduced (P less than or equal to 0.025) in cells harvested from spleens of FDA-transfused rats and tested fresh. Proliferative response of splenic lymphocytes to Con A was unaffected by transfusion with FDA (P greater than or equal to 0.078). Splenic hemolytic plaques in response to SRBC were unaffected if rats were transfused 3 days after immunization with SRBC and 1 day prior to study (P = 0.941), enhanced if rats were transfused 1 day after SRBC immunization and 3 days prior to study (P = 0.0015), and suppressed if rats were transfused 1 day before SRBC immunization and 5 days before study (P less than 0.0001). Transfusion with FDA causes transient decreases in identifiable T and B lymphocytes, depresses cytoplasmic IgG-positive B cells, does not affect proliferative response to Con A, does not affect an ongoing specific immune response, enhances an early specific immune response, and inhibits the induction of a specific immune response.
Hodges
G R
GR
Worley
S E
SE
Kemner
J M
JM
Abdou
N I
NI
Clark
G M
GM
D000818:Animals; D000921:Antibody-Producing Cells / Q000276:immunology; D003208:Concanavalin A / Q000494:pharmacology; D003593:Cytoplasm / Q000032:analysis; D004338:Drug Combinations / Q000008:administration & dosage / Q000494:pharmacology; D005078:Exchange Transfusion, Whole Blood; D005466:Fluorocarbons / Q000008:administration & dosage / Q000494:pharmacology*; D006895:Hydroxyethyl Starch Derivatives; D007121:Immunocompetence / Q000187:drug effects*; D007074:Immunoglobulin G / Q000032:analysis; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000145:classification / Q000187:drug effects / Q000276:immunology*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013154:Spleen / Q000166:cytology* / Q000187:drug effects
D004338:Drug Combinations; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; D007074:Immunoglobulin G; D003208:Concanavalin A; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination